Picture Berlin Partner Health Capital Computational Biology 2022 650x100px

Person › Details

Tim Van Hauwermeiren (Argen-X B.V.)

Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)

	Organisation	Argen-X B.V.
	Today	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Group	Argenx (Argen-X) (Group)
	Former/major organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Sanofi (Group) [since May 2011]
	Product	SIMPLE Antibody™ discovery platform

Record changed: 2022-01-21

Picture EBD Group BIO-Europe 2022 Leipzig 650x200px

More documents for Tim Van Hauwermeiren

[1] Argenx SE. (12/20/21). "Press Release: Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Darmstadt....
[2] Argenx SE. (7/14/21). "Press Release: Argenx to Host Virtual R&D Day on July 20, 2021". Breda....
[3] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
[4] Argenx SE. (6/1/21). "Press Release: Argenx Appoints Karl Gubitz as Chief Financial Officer". Dublin....
[5] Argenx SE. (1/6/21). "Press Release: Argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China". Breda, Shanghai & San Francisco, CA....
[6] Argenx SE. (1/4/21). "Press Release: Argenx to Present at 39th Annual J.P. Morgan Healthcare Conference". Breda & Ghent....
[7] Argenx SE. (3/14/19). "Press Release: Argenx to Receive First Clinical Milestone Payment for Product Candidate Developed". Breda & Ghent....
[8] Argenx SE. (3/4/19). "Press Release: Argenx to Present at Cowen and Company 39th Annual Health Care Conference". Breda & Ghent....
[9] Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent....
[10] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia". Breda & Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]